Company profile

Rooted in China with global vision

Very few domestic high-tech biomedical technology enterprises with the development, industrialization and commercialization ability of small molecular chemical drugs and macromolecular biological drug

In 2012, after Sihuan wholly acquired 100% equity, XZenith became the innovative drug subsidiary of Sihuan Pharmaceutical, a large domestic pharmaceutical group. The company began operating independently in 2018. And in 2020, it won the A round of strategic investment of national funds such as Future Industry Investment Fund II and Metropolitan Industrial Investment Fund. At the beginning of 2021, acquisition and integration of Beijing Combio( macromolecular biological pharmaceutical company). The B round of financing was successfully completed at the end of the same year.

After 10 years of incubation and construction of the Sihuan, XZenith has formed a complete new drug research and development system, with a whole industrial chain platform from the source of new drug approval, design discovery, pre-clinical pharmacological efficacy evaluation, CMC process development and pilot scale amplification, clinical development, registration and application, to industrialization and commercialization. Focusing on oncology, digestion, NASH and other fields, and committed to the development of class 1.1  innovative drugs.

  • Patents
  • Innovative Pipeline
  • Phase I-III & NDA
  • R&D personnel
research and develop


R & D of healthcare industry chain

The ability of continuous innovation Build the most competitive biomedical company